ITOS - ITeos Therapeutics Inc

10.15
0.020   0.197%

Share volume: 11,006,826
Last Updated: 08-28-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.03%

PREVIOUS CLOSE
CHG
CHG%
$10.13
0.02
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
34%
Profitability 36%
Dept financing 22%
Liquidity 58%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
43.77%
2 Year
-14.92%
Key data
Stock price
$10.15
P/E Ratio 
0.00
DAY RANGE
$10.14 - $10.17
EPS 
-$3.05
52 WEEK RANGE
$4.80 - $11.35
52 WEEK CHANGE
$34.97
MARKET CAP 
228.020 M
YIELD 
N/A
SHARES OUTSTANDING 
38.274 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-09-2025
BETA 
1.59
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Michel Detheux
Region: US
Website: iteostherapeutics.com
Employees: 90
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Iteos Therapeutics, Inc. engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials. EOS-448 is an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains.

Recent news